Developer docs
API playgroundTry for free, no card

Search company profiles

Kardium

Full company profile

uuid00004ad

Namestring
Kardium
Legal namestring
Kardium Inc.
Websiteurl
kardium.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Kardium is a privately held Canadian medical device company founded in 2007 and headquartered in Burnaby, British Columbia, that develops the Globe Pulsed Field System for the diagnosis and treatment of atrial fibrillation. The system integrates high-density cardiac mapping and pulsed field ablation in a single 122-electrode spherical array catheter, enabling true single-shot pulmonary vein isolation with proprietary GlobePulse waveform energy, real-time thermal contact sensing, and the optional Globe Positioning System (GPS) 3D navigation module. The PULSAR IDE pivotal trial of 183 patients across 12 international centers demonstrated 78% 12-month freedom from atrial arrhythmia, 0% device-related primary safety events, and 100% acute procedural success, supporting FDA Pre-Market Approval received in September 2025.

Kardium sells the Globe System directly to hospitals and electrophysiology centers through an enterprise field sales motion. The company holds a CE Mark for European sales (since June 2020) and operates Kardium GmbH in Dortmund, Germany, as its European commercial subsidiary. Following FDA PMA in September 2025, the company launched commercially in the United States in October 2025 with first procedures at St. Bernards Medical Center. The company has grown to nearly 600 employees (tripled from approximately 200 in 2022) and has raised approximately US$469M cumulatively across multiple rounds led by T. Rowe Price, Fidelity Management & Research, Janus Henderson Investors, Qatar Investment Authority, and others, with a stated intention to prepare for a potential IPO under CFO Koert VandenEnden. The intellectual property portfolio includes over 600 patents across the US, France, Germany, Great Britain, China, and India.

The company serves two primary segments: hospitals and electrophysiology centers performing catheter ablation procedures, and patients with paroxysmal or persistent atrial fibrillation, a condition affecting more than 8 million people in the US and nearly 50 million worldwide. Revenue is generated through hardware sales of the catheter, introducer sheath, generator, and mapping software sold via direct enterprise sales under multi-year hospital contracts with undisclosed unit pricing. Competitive positioning is anchored on integrated single-catheter mapping and ablation, 122-electrode architecture, and the safety profile of non-thermal pulsed field energy versus incumbent thermal ablation modalities.

Short descriptiontext

Kardium is a Canadian medical device company that develops the Globe Pulsed Field System, an integrated cardiac mapping and ablation platform using a 122-electrode catheter to treat atrial fibrillation, sold directly to hospitals and electrophysiology centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersBurnaby, Canada
HQ citystring
Burnaby
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac ablation systems, pulsed field ablation, electrophysiology medical devices, cardiac mapping catheters, atrial fibrillation treatment
Industry2 codes
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAC
Electrophysiology (Heart Rhythm)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Electrophysiology Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Globe Pulsed Field System Device Sales
TypeHardware Sales
Description

Sale of the Globe Pulsed Field System including the Globe Catheter (122-electrode spherical array), Globe Introducer sheath, Globe Mapping Software, and Globe PF Generator. Sold directly to hospitals and electrophysiology centers.

kardium.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Globe Pulsed Field System — medical device (no public pricing)
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed. Direct enterprise sales to hospitals and electrophysiology centers. Contact via sales representative.

kardium.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kardium develops and manufactures the Globe Pulsed Field System, an integrated cardiac mapping and ablation platform that combines a 122-electrode spherical array catheter with proprietary software and a pulsed field ablation generator to perform high-density mapping, pulmonary vein isolation, and customizable atrial ablation in a single device. The system is sold directly to hospitals and electrophysiology centers for the catheter-based treatment of atrial fibrillation. A legacy radiofrequency (RF) version, the Globe Mapping and Ablation System, is also commercially available in Europe.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 78% 12-month freedom from atrial arrhythmia in paroxysmal AF patients (PULSAR IDE pivotal trial, n=183)
+7 more records
Product overview1 text field

Kardium offers the Globe Pulsed Field System as its primary commercial product, consisting of multiple integrated components: the Globe Catheter (a 122-electrode spherical array), the Globe PF Generator, the Globe Introducer sheath, and proprietary Globe Mapping Software. The system uniquely combines high-density cardiac mapping and pulsed field ablation (PFA) in a single catheter, enabling single-shot pulmonary vein isolation with real-time thermal contact sensing. The company also offers the Globe Positioning System (GPS) as a 3D mapping and navigation add-on module. A legacy radiofrequency (RF) version (Globe Mapping and Ablation System) remains available in Europe. The portfolio centers on treating atrial fibrillation through integrated mapping and ablation technology.

Product and service2 records
1Globe Pulsed Field System
CategoryCardiac ablation system
Description

Integrated cardiac mapping and pulsed field ablation (PFA) system combining high-density mapping and ablation in a single 122-electrode spherical array catheter. FDA-approved (PMA, September 2025) for the treatment of paroxysmal atrial fibrillation; enables single-shot pulmonary vein isolation, customizable circumferential, linear, focal, and area lesion sets, and real-time thermal contact sensing without catheter exchanges. Sold directly to hospitals and electrophysiology centers.

2Globe Mapping and Ablation System (RF)
CategoryCardiac ablation system
Description

Earlier version of the Globe System using radiofrequency (RF) energy for ablation, featuring the same 122-electrode spherical array catheter for high-density mapping and RF ablation. CE-marked and commercially available in Europe via Kardium GmbH (Dortmund, Germany).

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kardium

Cardiac Electrophysiology Deviceskardium.com

Kardium is a Canadian medical device company that develops the Globe Pulsed Field System, an integrated cardiac mapping and ablation platform using a 122-electrode catheter to treat atrial fibrillation, sold directly to hospitals and electrophysiology centers.

What Kardium does

Kardium is a privately held Canadian medical device company founded in 2007 and headquartered in Burnaby, British Columbia, that develops the Globe Pulsed Field System for the diagnosis and treatment of atrial fibrillation. The system integrates high-density cardiac mapping and pulsed field ablation in a single 122-electrode spherical array catheter, enabling true single-shot pulmonary vein isolation with proprietary GlobePulse waveform energy, real-time thermal contact sensing, and the optional Globe Positioning System (GPS) 3D navigation module. The PULSAR IDE pivotal trial of 183 patients across 12 international centers demonstrated 78% 12-month freedom from atrial arrhythmia, 0% device-related primary safety events, and 100% acute procedural success, supporting FDA Pre-Market Approval received in September 2025.

Kardium sells the Globe System directly to hospitals and electrophysiology centers through an enterprise field sales motion. The company holds a CE Mark for European sales (since June 2020) and operates Kardium GmbH in Dortmund, Germany, as its European commercial subsidiary. Following FDA PMA in September 2025, the company launched commercially in the United States in October 2025 with first procedures at St. Bernards Medical Center. The company has grown to nearly 600 employees (tripled from approximately 200 in 2022) and has raised approximately US$469M cumulatively across multiple rounds led by T. Rowe Price, Fidelity Management & Research, Janus Henderson Investors, Qatar Investment Authority, and others, with a stated intention to prepare for a potential IPO under CFO Koert VandenEnden. The intellectual property portfolio includes over 600 patents across the US, France, Germany, Great Britain, China, and India.

The company serves two primary segments: hospitals and electrophysiology centers performing catheter ablation procedures, and patients with paroxysmal or persistent atrial fibrillation, a condition affecting more than 8 million people in the US and nearly 50 million worldwide. Revenue is generated through hardware sales of the catheter, introducer sheath, generator, and mapping software sold via direct enterprise sales under multi-year hospital contracts with undisclosed unit pricing. Competitive positioning is anchored on integrated single-catheter mapping and ablation, 122-electrode architecture, and the safety profile of non-thermal pulsed field energy versus incumbent thermal ablation modalities.

Kardium firmographics

Firmographics
Name
Kardium
Legal name
Kardium Inc.
Website
https://kardium.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Kardium is a Canadian medical device company that develops the Globe Pulsed Field System, an integrated cardiac mapping and ablation platform using a 122-electrode catheter to treat atrial fibrillation, sold directly to hospitals and electrophysiology centers.
Ownership category
akta.pro rank

Kardium industry classification

Industry
Product category
Cardiac Electrophysiology Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAC
Electrophysiology (Heart Rhythm)

Keywords

  • Cardiac ablation systems
  • Pulsed field ablation
  • Electrophysiology medical devices
  • Cardiac mapping catheters
  • Atrial fibrillation treatment

Where Kardium is headquartered

Location

Headquarters

HQ city
Burnaby
HQ country
Canada
HQ region
North America

Offices3 records

Markets served

Kardium business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Globe Pulsed Field System Device Sales: Sale of the Globe Pulsed Field System including the Globe Catheter (122-electrode spherical array), Globe Introducer sheath, Globe Mapping Software, and Globe PF Generator. Sold directly to hospitals and electrophysiology centers.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractGlobe Pulsed Field System — medical device (no public pricing)

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Kardium product offering

Product offering

Core offering

Kardium develops and manufactures the Globe Pulsed Field System, an integrated cardiac mapping and ablation platform that combines a 122-electrode spherical array catheter with proprietary software and a pulsed field ablation generator to perform high-density mapping, pulmonary vein isolation, and customizable atrial ablation in a single device. The system is sold directly to hospitals and electrophysiology centers for the catheter-based treatment of atrial fibrillation. A legacy radiofrequency (RF) version, the Globe Mapping and Ablation System, is also commercially available in Europe.

Product overview

Kardium offers the Globe Pulsed Field System as its primary commercial product, consisting of multiple integrated components: the Globe Catheter (a 122-electrode spherical array), the Globe PF Generator, the Globe Introducer sheath, and proprietary Globe Mapping Software. The system uniquely combines high-density cardiac mapping and pulsed field ablation (PFA) in a single catheter, enabling single-shot pulmonary vein isolation with real-time thermal contact sensing. The company also offers the Globe Positioning System (GPS) as a 3D mapping and navigation add-on module. A legacy radiofrequency (RF) version (Globe Mapping and Ablation System) remains available in Europe. The portfolio centers on treating atrial fibrillation through integrated mapping and ablation technology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Globe Pulsed Field System Integrated cardiac mapping and pulsed field ablation (PFA) system combining high-density mapping and ablation in a single 122-electrode spherical array catheter. FDA-approved (PMA, September 2025) for the treatment of paroxysmal atrial fibrillation; enables single-shot pulmonary vein isolation, customizable circumferential, linear, focal, and area lesion sets, and real-time thermal contact sensing without catheter exchanges. Sold directly to hospitals and electrophysiology centers.
  • Globe Mapping and Ablation System (RF) Earlier version of the Globe System using radiofrequency (RF) energy for ablation, featuring the same 122-electrode spherical array catheter for high-density mapping and RF ablation. CE-marked and commercially available in Europe via Kardium GmbH (Dortmund, Germany).

Quantifiable outcome

  • 78% 12-month freedom from atrial arrhythmia in paroxysmal AF patients (PULSAR IDE pivotal trial, n=183)
  • +7 more outcomes

Companies that use Kardium

Customer profile

Named customers7 records

Segments2 records

Ideal customer profiles1 record

Kardium technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Kardium partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Kardium competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

Kardium social profiles

Digital presence

Kardium compliance and trust

Trust signal

Compliance5 records

Kardium financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kardium leadership team

Management profile

Number of profiles

Profiles13 records

Kardium subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Kardium funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kardium M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kardium

What does Kardium do?

Kardium develops and manufactures the Globe Pulsed Field System, an integrated cardiac mapping and ablation platform that combines a 122-electrode spherical array catheter with proprietary software and a pulsed field ablation generator to perform high-density mapping, pulmonary vein isolation, and customizable atrial ablation in a single device. The system is sold directly to hospitals and electrophysiology centers for the catheter-based treatment of atrial fibrillation. A legacy radiofrequency (RF) version, the Globe Mapping and Ablation System, is also commercially available in Europe.

Is Kardium a public or private company?

Kardium is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kardium founded?

Kardium was founded in 2007. It employs 501 to 1,000 people.

Where is Kardium based?

Kardium is headquartered in Burnaby, Canada, in the North America region.

How does Kardium make money?

One revenue line is on record: globe Pulsed Field System Device Sales.

Does Kardium have an API?

No public API is recorded for Kardium.

What industry is Kardium in?

Kardium's product category is Cardiac Electrophysiology Devices. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAKABAC, Electrophysiology (Heart Rhythm). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TechcouverKardium Enrolls First Patient in North American Globe RegistryKardium enrolled the first patient in its Globe Registry, tracking the Globe Pulsed Field System in routine clinical practice. The registry will enroll up to 500 patients across Canada and the U.S., followed for 12 months to assess safety and effectiveness in atrial fibrillation. The company has secured FDA approval and completed first commercial procedures.BioSpaceKardium Launches the “Globe Durability Guarantee”™ – Highlighting the Outstanding Durability of the Globe® SystemKardium launched the Globe Durability Guarantee, crediting hospitals for Globe devices used in redo ablations if pulmonary vein reconnection occurs. The program is backed by PULSAR IDE data showing 95% durable isolation in repeat ablation, and the Globe System received FDA approval in August 2025.Medical BuyerKardium secures USD 22.5M funding from Canadian governmentKardium secured up to C$31.25M ($22.5M) from the Canadian government for its Globe pulsed field system in British Columbia. The funding supports a C$125M project to expand manufacturing of the cardiac mapping and ablation device, which received Health Canada and FDA approvals.Pulse 2.0Kardium Secures Up To $31.25 Million From Canada For $125 Million Globe System Manufacturing ExpansionKardium will receive up to $31.25 million from the Government of Canada through the Strategic Response Fund to expand cleanroom manufacturing capacity for its Globe Pulsed Field System in Vancouver, British Columbia. The $125 million project, with Canada's share at up to one-quarter, follows FDA approval in August 2025 and Health Canada approval in July 2026. Kardium said the expansion supports international demand.BetaKitFeds commit $31 million to help Kardium manufacture its heart device in BCKardium, a Burnaby, BC-based medical technology company, will receive up to $31.25 million from the Government of Canada through the Strategic Response Fund to expand its manufacturing of an atrial fibrillation device. The $125-million project aims to raise annual output from 500 to 30,000 units, creating 1,000 skilled jobs. German chemical giant Evonik Canada also received up to $68 million for a $150-million mRNA vaccine centre.Medical Device NetworkKardium secures $22.5m funding for pulsed field system manufacturingKardium has received up to C$31.25m ($22.5m) from the Government of Canada's Strategic Response Fund to support its C$125m project expanding production of the Globe pulsed field system in British Columbia. The funding covers enlargement of the company's Vancouver cleanroom facility. The device received Health Canada approval in July 2026 and FDA approval in August 2025.Mirage News$99M Boost for Canada's Life Sciences SectorCanada's government announced a nearly $100 million Strategic Response Fund investment in British Columbia life sciences firms Kardium Inc. and Evonik Canada Inc. Kardium's $125 million Burnaby manufacturing facility, funded up to $31.25 million, will expand cleanroom capacity from 500 to 30,000 units annually and create 1,000 jobs. Evonik's $150 million expansion, funded up to $68 million, will add 260 jobs.Financial PostKardium Receives Funding From the Government of Canada to Expand Manufacturing of the Globe® Pulsed Field System in British ColumbiaThe Government of Canada announced funding of up to $31.25 million through the Strategic Response Fund toward Kardium's $125 million investment to expand its Vancouver, British Columbia manufacturing of the Globe Pulsed Field System. The money will support a major cleanroom expansion, with the system approved by Health Canada in July 2026 and the FDA in August 2025.Business Wire BlogKardium Receives Funding From the Government of Canada to Expand Manufacturing of the Globe® Pulsed Field System in British ColumbiaThe Government of Canada announced funding of up to $31.25 million through the Strategic Response Fund toward Kardium's $125 million investment to expand its Vancouver, British Columbia manufacturing of the Globe Pulsed Field System. The money will support a major cleanroom facility expansion, with the system approved by Health Canada in July 2026 and the FDA in August 2025.FinancialContent Business PageKardium Receives Funding From the Government of Canada to Expand Manufacturing of the Globe® Pulsed Field System in British ColumbiaThe Government of Canada announced funding of up to $31.25 million through the Strategic Response Fund toward Kardium's $125 million investment to expand its Vancouver, British Columbia manufacturing capabilities. The money will support a new cleanroom facility to scale production of the Globe mapping and ablation catheter, approved by Health Canada in July 2026 and the FDA in August 2025.